Dasatinib (CAS 302962-49-8) Anticancer Pharmaceutical API

Dasatinib (CAS 302962-49-8) is a potent tyrosine kinase inhibitor (TKI) and anticancer API, celebrated for its targeted action against abnormal kinase activity in cancer cells. Its unique molecular structure enables it to bind to and inhibit multiple tyrosine kinases, blocking signaling pathways that drive cancer cell proliferation, survival, and metastasis. This high-purity pharmaceutical raw material meets stringent global quality standards, ensuring consistent potency and stability for clinical formulation.

Widely utilized in oncology drug development, it is a key ingredient for formulating medications to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), including resistant or refractory cases. Valued for its broad inhibitory spectrum and ability to penetrate cell membranes effectively, it addresses unmet medical needs for targeted cancer therapies. Choose this trusted anticancer API to develop high-efficacy, precision medicines that improve treatment outcomes for cancer patients.